Atopic Dermatitis: Seven-Market Drug Forecast and Market Analysis

1.1 AD market to experience significant growth from 2023-33
1.2 New players set to enter AD market
1.3 Opportunities remain for the treatment of AD
1.4 Novel systemic therapies dominate the late-stage pipeline
1.5 What do physicians think?

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or staging systems

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 7MM forecast methodology
4.4.1 Sources
4.4.2 Forecast assumptions and methods
4.4.3 Forecast assumption and methods: 12-month diagnosed prevalent cases of AD
4.4.4 Forecast assumptions and methods: 12-month diagnosed prevalent cases of AD by severity 4.5 Epidemiological Forecast for AD (2023-33)
4.5.1 12-month diagnosed prevalent cases of AD
4.5.2 Age-specific 12-month diagnosed prevalent cases of AD
4.5.3 Sex-specific 12-month diagnosed prevalent cases of AD
4.5.4 12-month diagnosed prevalent cases of AD by severity
4.6 Discussion
4.6.1 COVID-19 impact
4.6.2 Limitations of the analysis
4.6.3 Strengths of the analysis

5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management
5.2.1 Treatment approach

6.1 Overview

7.1 Overview
7.2 More personalized treatments through improved diagnosis
7.3 High cost of therapeutics
7.4 Lack of therapeutic options for CHE
7.5 Better long-term disease control and management

8.1 Overview
8.1.1 Rise of the JAK inhibitors
8.1.2 Rise of IL-inhibiting biologics
8.1.3 Personalized approach for AD
8.1.4 Promising effects of anti-OX40/OX40L therapies
8.2 Clinical trials design
8.2.1 Clinical trial design in AD
8.2.2 Clinical trial design in CHE
8.2.3 H2H in AD

9.1 Overview 9.2 Promising drugs in clinical development
9.2.1 Mild to moderate AD agents
9.2.2 Moderate-to-severe agents

10.1 Overview
10.2 Competitive assessment
10.2.1 Systemic agents
10.2.2 Topical agents

11.1 Overview
11.2 Deal-making trends

12.1 Global markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and barriers

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting methodology
13.4 Primary research - KOLs and payers interviewed for this report
13.4.1 KOLs 13.5 Primary research - prescriber survey
13.6 About the Authors
13.6.1 Analyst
13.6.2 Managing Analyst
13.6.3 Therapy Area Director
13.6.4 Epidemiologist
13.6.5 Reviewers
13.6.6 Vice President of Disease Intelligence and Epidemiology
13.6.7 Global Head of Pharma Research, Analysis, and Competitive Intelligence

• About the Analyst
• Contact the Publisher

Table 1: AD: Key metrics in the 7MM
Table 2: Risk factors and comorbidities for AD
Table 3: Treatment guidelines for AD
Table 4: AD approvals across 7MM
Table 5: Top 10 deals by value, 2019-25
Table 6: AD market - global drivers and barriers, 2023-33
Table 7: Key events impacting sales for AD in the US, 2023-33
Table 8: AD market - drivers and barriers in the US, 2023-33
Table 9: Key events impacting sales for AD in the 5EU, 2023-33
Table 10: AD market - drivers and barriers in the 5EU, 2023-33
Table 11: Key events impacting sales for AD in Japan, 2023-33
Table 12: AD market - drivers and barriers in Japan, 2023-33
Table 13: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for AD in 2023 and 2033
Figure 2: Analysis of the company portfolio gap in AD during the forecast period
Figure 3: Competitive assessment of the marketed and pipeline systemic drugs benchmarked against the SOC, Dupixent
Figure 5: Major drug targets in AD treatment
Figure 6: 7MM, 12-month diagnosed prevalence of AD, %, all ages, 2023
Figure 7: 7MM, sources used and not used to forecast the 12-month diagnosed prevalent cases of AD in the adult population
Figure 8: 7MM, sources used and not used to forecast the 12-month diagnosed prevalent cases of AD in the pediatric population
Figure 9: 7MM, sources used to forecast the 12-month diagnosed prevalent cases of AD in the adult population by severity
Figure 10: 7MM, sources used to forecast the 12-month diagnosed prevalent cases of AD in the pediatric population by severity
Figure 11 presents the 12-month diagnosed prevalent cases of AD in the 7MM in 2023.
Figure 11: 7MM, 12-month diagnosed prevalent cases of AD, N, both sexes, all ages, 2023
Figure 12: 7MM, 12-month diagnosed prevalent cases of AD by age, N, both sexes, 2023
Figure 13 presents the 12-month diagnosed prevalent cases of AD by sex in the 7MM in 2023.
Figure 13: 7MM, 12-month diagnosed prevalent cases of AD by sex, N, all ages, 2023
Figure 14 presents the 12-month diagnosed prevalent cases of AD by severity in the 7MM in 2023.
Figure 14: 7MM, 12-month diagnosed prevalent cases of AD by severity, both sexes, N, all ages, 2023
Figure 15: Flowchart of the diagnosis and management of AD, according to AAD
Figure 16: Unmet needs and opportunities in AD
Figure 17: Overview of the development pipeline in AD
Figure 18: Key late-stage trials for the promising mild-to-moderate pipeline agents that the analyst expects to be licensed for AD in the 7MM during the forecast period
Figure 19: Key late-stage trials for promising moderate-to-severe pipeline agents that the analyst expects to be licensed for AD in the 7MM during the forecast period
Figure 20: Competitive assessment of marketed and pipeline systemic drugs benchmarked against the SOC, Dupixent
Figure 21: Competitive assessment of the marketed and pipeline topical drugs, benchmarked against the SOC, TCs.
Figure 22: Analysis of the company portfolio gap in AD during the forecast period, 2023-33
Figure 23: Global (7MM) sales forecast by country for AD in 2023 and 2033
Figure 24: Global (7MM) Sales Forecast by MOA for AD in 2023 and 2033
Figure 25: Sales forecast by class for AD in the US in 2023 and 2033
Figure 26: Sales forecast by class for AD in the 5EU in 2023 and 2033
Figure 27: Sales forecast by class for AD in Japan in 2023 and 2033